455 related articles for article (PubMed ID: 18257767)
1. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
Sanger GJ; Alpers DH
Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
[TBL] [Abstract][Full Text] [Related]
2. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
Manabe N; Wong BS; Camilleri M
Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
[TBL] [Abstract][Full Text] [Related]
3. 5-HT4 receptor agonists: similar but not the same.
De Maeyer JH; Lefebvre RA; Schuurkes JA
Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
[TBL] [Abstract][Full Text] [Related]
4. Prokinetics and fundic relaxants in upper functional GI disorders.
Tack J
Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
[TBL] [Abstract][Full Text] [Related]
5. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
Tonini M; Pace F
Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacologic treatments of transit disorders].
Manz M; Meier R
Ther Umsch; 2007 Apr; 64(4):227-32. PubMed ID: 17663210
[TBL] [Abstract][Full Text] [Related]
8. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.
Peeters TL
Curr Opin Pharmacol; 2006 Dec; 6(6):553-8. PubMed ID: 17011824
[TBL] [Abstract][Full Text] [Related]
9. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
10. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
11. Motilin and ghrelin as prokinetic drug targets.
De Smet B; Mitselos A; Depoortere I
Pharmacol Ther; 2009 Aug; 123(2):207-23. PubMed ID: 19427331
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
Dobrek Ł; Thor PJ
Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
[TBL] [Abstract][Full Text] [Related]
13. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases.
Sanger GJ
Drug Discov Today; 2008 Mar; 13(5-6):234-9. PubMed ID: 18342799
[TBL] [Abstract][Full Text] [Related]
14. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
Gershon MD; Tack J
Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
[TBL] [Abstract][Full Text] [Related]
15. Translating 5-HT receptor pharmacology.
Sanger GJ
Neurogastroenterol Motil; 2009 Dec; 21(12):1235-8. PubMed ID: 19906028
[TBL] [Abstract][Full Text] [Related]
16. Motility disorders in the ICU: recent therapeutic options and clinical practice.
Röhm KD; Boldt J; Piper SN
Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):161-7. PubMed ID: 19202387
[TBL] [Abstract][Full Text] [Related]
17. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.
Boeckxstaens GE; Bartelsman JF; Lauwers L; Tytgat GN
Am J Gastroenterol; 2002 Jan; 97(1):194-7. PubMed ID: 11811166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
Camilleri M
Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
[No Abstract] [Full Text] [Related]
19. Prokinetics in the Management of Functional Gastrointestinal Disorders.
Quigley EMM
Curr Gastroenterol Rep; 2017 Sep; 19(10):53. PubMed ID: 28887755
[TBL] [Abstract][Full Text] [Related]
20. Promotility medications--now and in the future.
Karamanolis G; Tack J
Dig Dis; 2006; 24(3-4):297-307. PubMed ID: 16849857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
